Aerovate Therapeutics, Inc.

NASDAQ:AVTE

1.91 (USD) • At close September 18, 2024
Bedrijfsnaam Aerovate Therapeutics, Inc.
Symbool AVTE
Munteenheid USD
Prijs 1.91
Beurswaarde 55,137,307
Dividendpercentage 0%
52-weken bereik 1.25 - 32.415
Industrie Biotechnology
Sector Healthcare
CEO Mr. Timothy P. Noyes M.B.A.
Website https://aerovatetx.com

An error occurred while fetching data.

Over Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in

Vergelijkbare Aandelen

Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc.

MRSN

2.12 USD

Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc.

CMPX

1.63 USD

Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

67.22 USD

Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc.

KZR

0.576 USD

Icosavax, Inc. logo

Icosavax, Inc.

ICVX

15.31 USD

InterCure Ltd. logo

InterCure Ltd.

INCR

1.06 USD

Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

ANIK

25.47 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

8.91 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)